CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

(2020) Peter Dreger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation.

(2020) Maria-Luisa Schuber et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

(2020) Caron A. Jacobson et al.   JOURNAL OF CLINICAL ONCOLOGY

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

(2020) Chelsea C. Pinnix et al.   Blood Advances

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

(2020) David Sermer et al.   Blood Advances

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy

(2019) Victor A. Chow et al.   AMERICAN JOURNAL OF HEMATOLOGY

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

(2019) Rafael F. Duarte et al.   BONE MARROW TRANSPLANTATION

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

(2019) Tania Jain et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

(2019) E. González-Barca et al.   BONE MARROW TRANSPLANTATION

Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies

(2019) Na Wang et al.   BLOOD

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

(2019) Nirav N. Shah et al.   Blood Cancer Journal

Translating anti-CD19 CAR T-Cell therapy into clinical practice for relapsed/refractory diffuse large B-Cell lymphoma

(2018) Victor A. Chow et al.   BLOOD

The impact of advanced patient age on mortality after allogeneic hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: A retrospective study by the EBMT Lymphoma Working Party

(2018) Charalampia Kyriakou et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas

(2018) Carlos A. Ramos et al.   MOLECULAR THERAPY

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

(2016) Timothy S. Fenske et al.   BRITISH JOURNAL OF HAEMATOLOGY

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) H. Tilly et al.   ANNALS OF ONCOLOGY

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen

(2015) Alvaro Urbano-Ispizua et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

(2015) M Hahn et al.   BONE MARROW TRANSPLANTATION

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

(2015) S P Robinson et al.   BONE MARROW TRANSPLANTATION

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

(2015) E Van Den Neste et al.   BONE MARROW TRANSPLANTATION

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

(2014) Bertram Glass et al.   LANCET ONCOLOGY

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

(2012) Norbert Schmitz et al.   LANCET ONCOLOGY

Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation

(2011) Ron Ram et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome

(2011) Kitsada Wudhikarn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining the Intensity of Conditioning Regimens: Working Definitions

(2009) Andrea Bacigalupo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION